ecNumber*3.4.17.20#specificActivity*-999#specificActivityMaximum*#commentary*#organism*Homo sapiens#literature*28942#!ecNumber*3.4.17.20#specificActivity*-999#specificActivityMaximum*#commentary*#organism*Homo sapiens#literature*28943#!ecNumber*3.4.17.20#specificActivity*-999#specificActivityMaximum*#commentary*electroluminescence assay. The high sensitivity of the assay allows the determination of the activatable levels of TAFI in human and other animal plasma in presence of epsilon-aminocaproic acid, an active-site inhibitor that stabilizes TAFIa#organism*Canis lupus familiaris#literature*649320#!ecNumber*3.4.17.20#specificActivity*-999#specificActivityMaximum*#commentary*electroluminescence assay. The high sensitivity of the assay allows the determination of the activatable levels of TAFI in human and other animal plasma in presence of epsilon-aminocaproic acid, an active-site inhibitor that stabilizes TAFIa#organism*Chlorocebus aethiops#literature*649320#!ecNumber*3.4.17.20#specificActivity*-999#specificActivityMaximum*#commentary*electroluminescence assay. The high sensitivity of the assay allows the determination of the activatable levels of TAFI in human and other animal plasma in presence of epsilon-aminocaproic acid, an active-site inhibitor that stabilizes TAFIa#organism*Homo sapiens#literature*649320#!ecNumber*3.4.17.20#specificActivity*-999#specificActivityMaximum*#commentary*electroluminescence assay. The high sensitivity of the assay allows the determination of the activatable levels of TAFI in human and other animal plasma in presence of epsilon-aminocaproic acid, an active-site inhibitor that stabilizes TAFIa#organism*Macaca mulatta#literature*649320#!ecNumber*3.4.17.20#specificActivity*-999#specificActivityMaximum*#commentary*electroluminescence assay. The high sensitivity of the assay allows the determination of the activatable levels of TAFI in human and other animal plasma in presence of epsilon-aminocaproic acid, an active-site inhibitor that stabilizes TAFIa#organism*Rattus norvegicus#literature*649320#!ecNumber*3.4.17.20#specificActivity*-999#specificActivityMaximum*#commentary*binding capacity of recombinant wild-type and chimeric mutant isozymes to fibrinogen and plasminogen, overview#organism*Homo sapiens#literature*652560#!ecNumber*3.4.17.20#specificActivity*-999#specificActivityMaximum*#commentary*#organism*Homo sapiens#literature*653008#!ecNumber*3.4.17.20#specificActivity*-999#specificActivityMaximum*#commentary*in vivo arteriovenous shunt thrombosis model, ex vivo clot lysis assay#organism*Rattus norvegicus#literature*653008#!ecNumber*3.4.17.20#specificActivity*-999#specificActivityMaximum*#commentary*coupled assay methods, overview#organism*Homo sapiens#literature*668287#!ecNumber*3.4.17.20#specificActivity*-999#specificActivityMaximum*#commentary*assay development and optimization, overview#organism*Homo sapiens#literature*670058#!ecNumber*3.4.17.20#specificActivity*-999#specificActivityMaximum*#commentary*plasminogen and fibrinogen binding activity of the enzyme#organism*Homo sapiens#literature*670059#!ecNumber*3.4.17.20#specificActivity*-999#specificActivityMaximum*#commentary*develpoment of a fast kinetic assay for plasma enzyme quantification, coupled assay with pyruvate kinase/lactate dehydrogenase in microtiter plates, reaction scheme overview#organism*Homo sapiens#literature*670060#!ecNumber*3.4.17.20#specificActivity*-999#specificActivityMaximum*#commentary*TAFI activity changes during gestation#organism*Homo sapiens#literature*670931#!ecNumber*3.4.17.20#specificActivity*-999#specificActivityMaximum*#commentary*enzyme plasma concentration of healthy male persons, correlation of enzyme plasma concentration to cardiovascular diseases, overview#organism*Homo sapiens#literature*670940#!ecNumber*3.4.17.20#specificActivity*-999#specificActivityMaximum*#commentary*hemodynamics in untreated hearts of dogs and hearts treated with enzyme inhibitor MERGETPA and/or plasminogen activator, overview#organism*Canis lupus familiaris#literature*670947#!ecNumber*3.4.17.20#specificActivity*0.017#specificActivityMaximum*#commentary*substrate hippuryl-L-Arg#organism*Homo sapiens#literature*28933#!ecNumber*3.4.17.20#specificActivity*8#specificActivityMaximum*#commentary*substrate hippuryl-L-Lys#organism*Homo sapiens#literature*28945#!ecNumber*3.4.17.20#specificActivity*11.4#specificActivityMaximum*#commentary*substrate hippuryl-L-Arg#organism*Homo sapiens#literature*28945#!ecNumber*3.4.17.20#specificActivity*2000#specificActivityMaximum*#commentary*#organism*Homo sapiens#literature*28944#